China’s drugs offer lifeline for global pharma as it peers over the patent cliff

China’s drugs offer lifeline for global pharma as it peers over the patent cliff

Out-licensing of clinical candidates from China has increased dramatically over the last five years, as the world’s pharma companies shore up their pipelines in anticipation of an approaching patent cliff for several blockbusters. A recent GlobalData report describes the rise in licensing deals…

China’s drugs offer lifeline for global pharma as it peers over the patent cliff - Pharmaceutical Technology

A spike in licensing of candidates developed in China this year is a sign of the country’s transition in the global pharma space.

Surge in out-licensing deals drive China’s international pharma collaborations: GlobalData - Express Pharma

China’s out-licensing deals have significantly increased over the last five years, showcasing the country as a source of innovative drugs. The licensing agreements provide global recognition as well as validation for China’s advancements in drug development. With China-origin innovations becoming must-watch opportunities for global pharma, collaborations with the US and EU are reaching record scale and value, says GlobalData. GlobalData’s latest…